MedTrace Logo

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

NCT01893801 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-05-29

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).

Conditions

  • Stage IV Pancreatic Cancer

Interventions

DRUG

nab-paclitaxel

25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle

DRUG

Cisplatin

25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle

DRUG

gemcitabine

1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle

Sponsors & Collaborators

  • Translational Genomics Research Institute

    collaborator OTHER

  • Honor Health - Clinical Trials

    collaborator UNKNOWN

  • Cancer Research and Biostatistics Clinical Trials Consortium

    collaborator NETWORK

  • Pancreatic Cancer Research Team

    lead OTHER

Principal Investigators

  • Gayle S Jameson, MSN ACNP-BC · Scottsdale Health Care

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-04-30
Completion
2017-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01893801 on ClinicalTrials.gov